Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Chengdu Jingze Biopharmaceutical
Chengdu, Sichuan, Chinajingzepharma.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
01
Overview
Jingze Biopharmaceutical's pipeline includes one NDA-approved biosimilar (JZB30), three additional clinical-stage products (including a Phase 3 biosimilar and first-in-class biologics), and multiple preclinical programs. JZB30 received NDA approval from the NMPA in 2025.
- Therapeutic areas
- Men's HealthWomen's HealthOphthalmology
- Modalities
- BiologicBiosimilarMonoclonal antibodyHormoneSmall interfering RNAFc fusion protein
- Industry
- Biotech
02
Partnerships
Jingfeng Pharmaceutical (strategic investor)
Beyond the preview
Go deeper on Chengdu Jingze Biopharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Chengdu Jingze Biopharmaceutical.